76.17
price down icon1.83%   -1.42
after-market After Hours: 76.20 0.03 +0.04%
loading
Merck Co Inc stock is traded at $76.17, with a volume of 12.27M. It is down -1.83% in the last 24 hours and down -8.44% over the past month. Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
See More
Previous Close:
$77.59
Open:
$77.43
24h Volume:
12.27M
Relative Volume:
0.78
Market Cap:
$191.27B
Revenue:
$63.92B
Net Income/Loss:
$17.43B
P/E Ratio:
11.09
EPS:
6.87
Net Cash Flow:
$17.04B
1W Performance:
-1.05%
1M Performance:
-8.44%
6M Performance:
-26.13%
1Y Performance:
-39.59%
1-Day Range:
Value
$75.59
$77.72
1-Week Range:
Value
$75.59
$78.36
52-Week Range:
Value
$73.31
$134.63

Merck Co Inc Stock (MRK) Company Profile

Name
Name
Merck Co Inc
Name
Phone
908-740-4000
Name
Address
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Name
Employee
75,000
Name
Twitter
@Merck
Name
Next Earnings Date
2025-02-04
Name
Latest SEC Filings
Name
MRK's Discussions on Twitter

Compare MRK with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
MRK
Merck Co Inc
76.17 193.30B 63.92B 17.43B 17.04B 6.87
Drug Manufacturers - General icon
LLY
Lilly Eli Co
719.39 670.62B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
152.43 368.56B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
ABBV
Abbvie Inc
183.09 321.13B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
111.87 222.75B 53.22B 12.86B 14.85B 6.39
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
68.60 303.04B 43.59B 15.04B 10.74B 3.3766

Merck Co Inc Stock (MRK) Upgrades & Downgrades

Date Action Analyst Rating Change
May-14-25 Downgrade Citigroup Buy → Neutral
Apr-22-25 Initiated Cantor Fitzgerald Neutral
Feb-18-25 Downgrade Deutsche Bank Buy → Hold
Feb-10-25 Downgrade TD Cowen Buy → Hold
Jan-08-25 Downgrade Truist Buy → Hold
Dec-20-24 Downgrade BMO Capital Markets Outperform → Market Perform
Dec-10-24 Resumed BofA Securities Buy
Dec-04-24 Upgrade HSBC Securities Hold → Buy
Nov-15-24 Initiated Wolfe Research Peer Perform
Nov-11-24 Downgrade Daiwa Securities Buy → Neutral
Oct-17-24 Initiated Bernstein Mkt Perform
Mar-11-24 Downgrade Societe Generale Hold → Sell
Jan-04-24 Upgrade TD Cowen Market Perform → Outperform
Nov-09-23 Initiated Deutsche Bank Buy
Oct-27-23 Upgrade BMO Capital Markets Market Perform → Outperform
Oct-20-23 Upgrade UBS Neutral → Buy
Jul-14-23 Initiated HSBC Securities Hold
Apr-13-23 Upgrade Citigroup Neutral → Buy
Mar-28-23 Downgrade Societe Generale Buy → Hold
Mar-13-23 Downgrade Wells Fargo Overweight → Equal Weight
Mar-06-23 Initiated Jefferies Buy
Feb-22-23 Upgrade Wolfe Research Peer Perform → Outperform
Jan-04-23 Upgrade BofA Securities Neutral → Buy
Nov-18-22 Initiated Credit Suisse Outperform
Oct-10-22 Upgrade Guggenheim Neutral → Buy
Sep-14-22 Upgrade Berenberg Hold → Buy
Jul-06-22 Upgrade Daiwa Securities Neutral → Buy
Jun-06-22 Resumed SVB Leerink Outperform
Apr-06-22 Resumed Morgan Stanley Equal-Weight
Dec-17-21 Initiated Goldman Buy
Dec-16-21 Initiated Daiwa Securities Neutral
Dec-13-21 Downgrade UBS Buy → Neutral
Dec-09-21 Initiated Wells Fargo Overweight
Dec-07-21 Downgrade Guggenheim Buy → Neutral
Nov-29-21 Downgrade Citigroup Buy → Neutral
Nov-19-21 Initiated BMO Capital Markets Market Perform
Nov-01-21 Upgrade Argus Hold → Buy
Sep-07-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Jul-27-21 Resumed Truist Buy
May-20-21 Downgrade Argus Buy → Hold
Apr-07-21 Resumed RBC Capital Mkts Sector Perform
Nov-10-20 Resumed Bernstein Outperform
Sep-29-20 Initiated Berenberg Hold
Aug-03-20 Upgrade Goldman Neutral → Buy
Jun-12-20 Downgrade Wolfe Research Outperform → Peer Perform
Feb-27-20 Initiated Barclays Overweight
Jan-07-20 Initiated RBC Capital Mkts Sector Perform
Oct-17-19 Resumed BofA/Merrill Neutral
Aug-16-19 Initiated SVB Leerink Outperform
Jul-03-19 Initiated Mizuho Buy
May-28-19 Initiated Goldman Neutral
May-13-19 Upgrade Atlantic Equities Neutral → Overweight
Oct-16-18 Reiterated Citigroup Buy
Oct-09-18 Resumed Guggenheim Buy
Apr-23-18 Upgrade Goldman Neutral → Buy
Apr-17-18 Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-05-18 Upgrade Barclays Equal Weight → Overweight
Mar-12-18 Upgrade Leerink Partners Mkt Perform → Outperform
Feb-14-18 Reiterated Leerink Partners Mkt Perform
Feb-07-18 Reiterated Morgan Stanley Equal-Weight
Jan-16-18 Upgrade SunTrust Hold → Buy
View All

Merck Co Inc Stock (MRK) Latest News

pulisher
May 27, 2025

Merck Proves Why It’s Still A Top Pharma Pick (NYSE:MRK) - Seeking Alpha

May 27, 2025
pulisher
May 27, 2025

Merck (MRK) Options Activity Highlights Bullish Sentiment | MRK Stock News - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Merck & Co., Inc. Declares Quarterly Dividend for the Third Quarter of 2025, Payable on July 8, 2025 - marketscreener.com

May 27, 2025
pulisher
May 27, 2025

Merck sets $0.81 quarterly dividend for Q3 2025 By Investing.com - Investing.com India

May 27, 2025
pulisher
May 27, 2025

Merck Announces Third-Quarter 2025 Dividend - BioSpace

May 27, 2025
pulisher
May 27, 2025

Merck Announces Third-Quarter 2025 Dividend Of $0.81 Per Share - marketscreener.com

May 27, 2025
pulisher
May 27, 2025

NLPC Warns Merck About ‘Materially Misleading’ Shareholders on DEI - National Legal And Policy Center

May 27, 2025
pulisher
May 27, 2025

Rapid Micro Biosystems Announces Appointment of Dr. Dafni Bika to Board of Directors - GlobeNewswire Inc.

May 27, 2025
pulisher
May 26, 2025

Merck & Co.’s SWOT analysis: stock faces keytruda LOE, china challenges - Investing.com

May 26, 2025
pulisher
May 23, 2025

Merck Issues Statement On Potential Reduced Dosing Recommendation For Gardasil 9 - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

Merck: Dividend Near A 12-Year High, But I Won't BuyHere's Why (NYSE:MRK) - Seeking Alpha

May 23, 2025
pulisher
May 23, 2025

Merck: Defensive Yield Meets Long-Term Optionality - Seeking Alpha

May 23, 2025
pulisher
May 23, 2025

Merck (MRK) Advises Against Changing Gardasil Dosing Schedule - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Merck contends single dosing of Gardasil vaccine should be avoided - Seeking Alpha

May 23, 2025
pulisher
May 23, 2025

Merck (MRK) Stands Firm on Gardasil 9 Dosing Standards | MRK Stock News - GuruFocus

May 23, 2025
pulisher
May 22, 2025

Merck: Undervalued In Light Of Key Risks (NYSE:MRK) - Seeking Alpha

May 22, 2025
pulisher
May 22, 2025

Merck & Co. Stock: Inventory Doesn’t Lie (NYSE:MRK) - Seeking Alpha

May 22, 2025
pulisher
May 22, 2025

July 3rd Options Now Available For Merck (MRK) - Nasdaq

May 22, 2025
pulisher
May 22, 2025

Merck to Participate in the Bernstein 41st Annual Strategic Decisions Conference - BioSpace

May 22, 2025
pulisher
May 21, 2025

Merck & Co., Inc. (MRK): A Bull Case Theory - Insider Monkey

May 21, 2025
pulisher
May 21, 2025

Merck and imec to develop a disruptive MicroPhysiological Systems platform - New Electronics

May 21, 2025
pulisher
May 20, 2025

Neuphoria Therapeutics Inc. SEC 10-Q Report - TradingView

May 20, 2025
pulisher
May 20, 2025

Merck (NYSE:MRK) Collaborates With Antengene For Promising Cancer Therapy Evaluation - Yahoo Finance

May 20, 2025
pulisher
May 20, 2025

Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-022 (CLDN18.2 ADC) In Combination with KEYTRUDA® (pembrolizumab) - BioSpace

May 20, 2025
pulisher
May 20, 2025

Chloramine B Market to Witness Massive Growth by 2032 | Merck & Co., Inc., Anhui BBCA Pharmaceuticals Co., Ltd - openPR.com

May 20, 2025
pulisher
May 20, 2025

Merck & Co., Inc.'s (NYSE:MRK) CEO Will Probably Find It Hard To See A Huge Raise This Year - simplywall.st

May 20, 2025
pulisher
May 20, 2025

Berenberg Adjusts Price Target on Merck & Co. to $100 From $115, Maintains Buy Rating - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

Merck Announces Collaboration With Imec To Develop Disruptive Microphysiological Systems Platform - marketscreener.com

May 20, 2025
pulisher
May 19, 2025

UBS maintains Buy on Merck stock, reiterates $105 target By Investing.com - Investing.com India

May 19, 2025
pulisher
May 19, 2025

MRK November 21st Options Begin Trading - Nasdaq

May 19, 2025
pulisher
May 19, 2025

Bio/Pharmaceutical Outsourcing Report, March 2025 Edition - GlobeNewswire Inc.

May 19, 2025
pulisher
May 19, 2025

UBS maintains Buy on Merck stock, reiterates $105 target - Investing.com

May 19, 2025
pulisher
May 19, 2025

Merck: Phase 3 trial begins in esophageal cancer - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

CytomX begins trial of new melanoma treatment with Merck therapy By Investing.com - Investing.com India

May 19, 2025
pulisher
May 19, 2025

Breakthrough Cancer Drug Enters Phase 3 Trial: Merck Targets Deadly Esophageal Cancer with 15% Survival Rate - Stock Titan

May 19, 2025
pulisher
May 16, 2025

Merck: progress report in hypertension (PAH) - marketscreener.com

May 16, 2025
pulisher
May 16, 2025

Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society’s (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial Hypertension - BioSpace

May 16, 2025
pulisher
May 16, 2025

Merck to Present New Clinical and Outcomes Research Data at The - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Merck's WINREVAIR Shows Promising Long-Term Safety Profile in Largest PAH Clinical Trial Analysis Yet - Stock Titan

May 16, 2025
pulisher
May 16, 2025

MSD’s Phase III trial of Keytruda meets endpoint for treating ovarian cancer - Clinical Trials Arena

May 16, 2025
pulisher
May 16, 2025

[Pfizer Inc, AstraZeneca, Merck & Co. Inc] Breakthroughs In Bladder Cancer Treatment Market Research 2025 - openPR.com

May 16, 2025
pulisher
May 16, 2025

Merck & Co., Inc. (NYSE:MRK) Earns “Neutral” Rating from Citigroup - Defense World

May 16, 2025
pulisher
May 16, 2025

Traders Buy Large Volume of Put Options on Merck & Co., Inc. (NYSE:MRK) - Defense World

May 16, 2025
pulisher
May 16, 2025

Merck Continues to Deliver Growth in Turbulent Times - chemeurope.com

May 16, 2025
pulisher
May 15, 2025

Merck’s Welireg Adrenal Tumor Rollout Targets Specialized Centers - insights.citeline.com

May 15, 2025
pulisher
May 15, 2025

Decoding Merck & Co's Options Activity: What's the Big Picture? - Nasdaq

May 15, 2025
pulisher
May 15, 2025

Merck Data Shows Positive Outcomes For Ovarian Cancer Patients Treated With KeytrudaMerck & Co (NYSE:MRK) - Benzinga

May 15, 2025
pulisher
May 15, 2025

Why Merck & Co., Inc. (MRK) Is Among the Best Cheap Stocks to Buy Now for Beginners - Insider Monkey

May 15, 2025
pulisher
May 15, 2025

Merck & Co., Inc. (MRK): One of the Best Dividend Growth Stocks with High Yields - Insider Monkey

May 15, 2025
pulisher
May 15, 2025

Jefferies not seeing significant impact to Merck, Bristol from draft guidance - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

Merck brings another big business to small town De Soto - NewsBreak: Local News & Alerts

May 15, 2025

Merck Co Inc Stock (MRK) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_general GSK
$39.18
price down icon 0.66%
drug_manufacturers_general NVO
$68.60
price down icon 2.61%
$278.40
price down icon 0.38%
drug_manufacturers_general NVS
$111.87
price down icon 1.18%
$108.44
price down icon 0.60%
Cap:     |  Volume (24h):